OMDA
Omada Health, Inc.14.61
+0.02+0.14%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Conservative guide; new-product upside
Q&A framed 2026 guidance as deeply conservative, layering historical trends atop 886k members with zero baked-in gains from GLP-1 Flex Care, prescribing, cholesterol, or enrollment improvements—yet early selling season tracked strong, with covered lives up over 5M. Flex Care pulls higher fees from the 55% of employers dodging GLP drug costs, while new programs price accretive to flat ~$300 ARPU. AI tools like Spark boost engagement; unique data insulates versus disruption. Multi-condition traction surges amid point-solution fatigue. Guidance leaves upside on the table. Management stayed crisp on margin drivers like staffing tweaks. Watch product ramps, enrollment yield.
Key Stats
Market Cap
846.04MP/E (TTM)
-Basic EPS (TTM)
-0.46Dividend Yield
0%Recent Filings
10-K
FY2025 results
Omada Health narrowed its FY2025 net loss to $12.8M from $47.1M in 2024, driven by revenue surging 53% to $260.2M on 886K total members (up 55% y/y), with services up 53% and hardware 60%. Q4 momentum accelerated member growth while gross margin expanded 5.1ppt to 65.7% via Care Team efficiencies and tech leverage, yet opEx rose 25% on sales/marketing. Debt-free post-IPO with $222M cash. Customer concentration persists with top partners at 77% revenue. Seasonality risks loom from open enrollment timing.
8-K
Revenue up 58%, profitable Q4
8-K
Q4 revenue $72-74M, up 50-54%
10-Q
Q3 FY2025 results
Omada Health crushed Q3 with revenue jumping 49% y/y to $68M, fueled by 53% member growth to 831K, while gross margin expanded 3.5 points to 66% via Care Team efficiencies. Operating loss narrowed to $2.5M from $8.5M y/y as sales/marketing scaled with topline; net loss shrank to $3.2M or $(0.06)/diluted share on 57.7M shares (anti-dilutive). Cash swelled to $199M post-IPO-fueled debt payoff, with YTD FCF positive at ~$0.4M (derived). Debt-free now. Yet customer concentration with Cigna affiliates persists.
8-K
Q3 revenue up 49%, profitable EBITDA
Omada Health crushed Q3 with revenue jumping 49% to $68M and members surging 53% to 831,000 versus last year. Net loss shrank to $3M from $9M; first positive Adjusted EBITDA of $2M. Announced GLP-1 prescribing launch. Raised full-year revenue outlook to $251.5M-$254.5M. Path to profitability accelerates.
IPO
Website
Employees
Sector
Industry